Last reviewed · How we verify
Pro-Banthine (PROPANTHELINE)
Pro-Banthine (Propanteline) is a small molecule anticholinergic medication that targets the muscarinic acetylcholine receptor M4. Originally developed and currently owned by Shire, it was first approved by the FDA in 1953 for the treatment of peptic ulcers. As an off-patent medication, Pro-Banthine is available as a generic product from multiple manufacturers. Key safety considerations include its potential to cause dry mouth, blurred vision, and constipation due to its anticholinergic effects. Its short half-life of 1.6 hours allows for rapid elimination from the body.
At a glance
| Generic name | PROPANTHELINE |
|---|---|
| Sponsor | Shire |
| Drug class | Anticholinergic |
| Target | Muscarinic acetylcholine receptor M4 |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
| First approval | 1953 |
Approved indications
- Peptic ulcer
Common side effects
Key clinical trials
- A Randomized, Placebo-Controlled Study to Assess the Efficacy of Propantheline for the Treatment of Overactive Bladder (PHASE1)
- Compare the Therapeutic Effect Treated With Tamsulosin and Progesterone After ESWL( Extra Corporeal Shock Wave Lithotripsy) in Urinary Calculus (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pro-Banthine CI brief — competitive landscape report
- Pro-Banthine updates RSS · CI watch RSS